CAPZB: A Potential Drug Target and Biomarker for Muscle Z-Line Subunit Beta

Target Name: CAPZB

NCBI ID: G832

CAPZB

CAPZB: A Potential Drug Target and Biomarker for Muscle Z-Line Subunit Beta

Abstract:

CAPZB (Capping actin protein of muscle Z-line subunit beta), transcript variant 2, is a gene that encodes a protein involved in muscle contractions. The Z-line subunit beta is a critical protein that forms the Z-line, which is a thin filament that plays a crucial role in muscle contraction. The CAPZB gene has been associated with various muscle-related diseases, including muscular dystrophy, myopathies, and neuromuscular disorders. In this article, we will discuss the potential drug targets and biomarkers associated with CAPZB , as well as its current research status and future prospects.

Introduction:

Muscle contraction is a critical process that allows humans to move and perform various activities. The Z-line subunit beta (CAPZB) is a key protein that forms the Z-line, which is a thin filament that plays a crucial role in muscle contraction. CAPZB is a member of the actin protein family, which includes other proteins involved in muscle contraction, such as myosin and myosin light chain. Z-line subunit beta is expressed in a variety of muscle fibers, including slow-twitch and fast-twitch fibers.

Diseases associated with CAPZB:

CAPZB is associated with various muscle-related diseases, including muscular dystrophy, myopathies, and neuromuscular disorders. Muscular dystrophy is a group of genetic disorders characterized by progressive muscle weakness and degenerative changes. Myopathies are diseases that cause muscle growth or dysfunction. Neuromuscular disorders are conditions that affect the communication between the brain and muscles.

Potential drug targets:

CAPZB has been identified as a potential drug target for treating various muscle-related diseases. One of the main targets of CAPZB is the regulation of muscle contraction. The CAPZB protein plays a critical role in the regulation of muscle contraction by interacting with the myosin protein .Research shows that CAPZB interacts with myosin to regulate muscle contraction and contractility.

In addition to its role in muscle contraction, CAPZB has also been identified as a potential biomarker for various muscle-related diseases. The levels of CAPZB have been detected in muscle biopsy samples from patients with various muscle-related diseases, including muscular dystrophy, myopathies , and neuromuscular disorders. This suggests that CAPZB may be a useful biomarker for these diseases.

Future prospects:

The research on CAPZB is in its infancy, and there is much to be learned about its functions and potential drug targets. As research continues to advance, it is likely that the role of CAPZB in muscle contraction and disease will become increasingly understood.

Conclusion:

CAPZB is a gene that encodes a protein involved in muscle contractions. It has been associated with various muscle-related diseases, including muscular dystrophy, myopathies, and neuromuscular disorders. As research continues to advance, the potential drug targets and biomarkers associated with CAPZB will become increasingly understood. While the full potential of CAPZB is yet to be discovered, its research has the potential to lead to new treatments and therapies for various muscle-related diseases.

Protein Name: Capping Actin Protein Of Muscle Z-line Subunit Beta

Functions: F-actin-capping proteins bind in a Ca(2+)-independent manner to the fast growing ends of actin filaments (barbed end) thereby blocking the exchange of subunits at these ends. Unlike other capping proteins (such as gelsolin and severin), these proteins do not sever actin filaments. Plays a role in the regulation of cell morphology and cytoskeletal organization. Forms, with CAPZB, the barbed end of the fast growing ends of actin filaments in the dynactin complex and stabilizes dynactin structure. The dynactin multiprotein complex activates the molecular motor dynein for ultra-processive transport along microtubules (By similarity)

The "CAPZB Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CAPZB comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets